• Addition of HBOT to the classic management of diabetic ulcer, has been shown to improve rates of infection control and results in negative cultures, when compared to classic treatment alone
  • Published results have shown that addition of HBOT to the treatment of patients with diabetic gangrene, led to significant healing rates compared to patients without HBOT (16 of 18 in the HBOT group, compared to 1 of 10). In another, more carefully designed trial, diabetic ulcer patients were treated by a Surgeon with thorough debridement and vascular surgery where needed . Addition of HBOT had the following effects: Enhanced angiogenesis with significant increase of tissue Oxygen measured at the end of HBOT sessions, and significant reduction of amputations needed for definite treatment (1 of 3 patients needed amputation in the non-HBOT group, 1 of 12 in the HBOT group)
  • Concerning cost-effectiveness of HBO Therapy: Results of HBOT in efficient treatment of diabetic – chronic ulcers, combined with reduction of amputations and costs for dressings lead to cost reduction greater than the actual cost of HBOT. Total care cost reduction up to 20% has been reported when HBOT is added, as well as reduced morbidity. Furthermore, there is sufficient reduction of social and psychological burden that cannot be measured, for each one amputation avoided.